Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer

Stopped early · Phase 2

Conditions studied: Pancreatic Cancer

In brief

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with stage III or stage IV pancreatic cancer.

Key facts

Study ID

NCT00470535

Run by

Roswell Park Cancer Institute

People needed

18

Starts

2007-01-01

Expected to finish

2010-09-01

Last updated by the study team

2017-02-23

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Roswell Park Cancer Institute — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.